A drug that modulates skeletal muscle glucose uptake for the treatment of type 2 diabetes could have significant therapeutic impact, and these findings should be considered when determining the effectiveness of targeting CRHR2 or similar GPCRs for this purpose. This evidence concerns the gene CRHR2 and type 2 diabetes mellitus.